The serological positivity of immunoglobulin IgG4 in patients with pancreatic carcinoma

Česká verzia

Authors: Petr Dítě ¹ ; I. Novotný ²; Z. Kala ³; M. Hermanová ⁴; H. Nechutová ⁵; J. Dvořáčková ⁶; Arnošt Martínek ¹ ; J. Trna ⁵
Authors place of work: Akademické centrum digestivní onkologie, Lékařská fakulta Ostrava, 2Endoskopické centrum, Masarykův onkologický ústav, Brno, 3Chirurgická klinika, FN Brno, 4Ústav patologie FN u sv. Anny v Brně, 5Interní gastroenterologická klinika, FN Brno, 6Ústav patolo ¹
Published in the journal: Gastroent Hepatol 2012; 66(3): 187-190
Category: Clinical and Experimental Gastroenterology: Original Article

Summary

The group of illnesses marked by high level of immunoglobulin G4 (IgG4) in blood serum are designated as IgG4-associated diseases. The most common disease in this group is an autoimmune form of pancreatitis. In its initial stage, this is characterised by mild, subjective complaints, which more resemble stomach discomfort. The first symptom, however, may be a painless, obstructive icterus. Imaging methods can be used to view the diffuse or segmental enlargement of the pancreas, which can cause difficulties in distinguishing it from a pancreatic carcinoma. A characteristic feature of the autoimmune form of pancreatitis, and in particular first type, is an increased level of IgG4 of the blood serum, where a 97% specificity and 95% sensitivity predict a diagnosis of the autoimmune form of pancreatitis. Case studies have also appeared in specialist literature showing a high level of IgG4 in patients with a pancreatic carcinoma. In our prospective study, we therefore examined a set of patients with histologically verified pancreatic carcinomas and determined the level of IgG4 in their blood serum.

Materials and methods:
Over the course of a 52-month period, the level of IgG4 in blood serum was analysed using the nephelometric method in 81 patients with histologically verified pancreatic carcinomas. According to standards set in literature, the borderline IgG4 value is higher than 135 mg/dl.

Results:
In the observed group an IgG4 level exceeding 135 mg/dl was demonstrated in 8 patients (9.8). The average IgG4 level was 173 mg/dl, i.e. 12.9% higher against the borderline value. Amongst the patients showing a greater IgG4 value were five in whom the creation of a carcinoma during the course of chronic pancreatitis could be anticipated, as the diagnosis of chronic pancreatitis was determined more than 5 years before the determination of the diagnosis of the pancreatic carcinoma. None of the 8 patients with a higher IgG4 value showed any diagnostic signs of the autoimmune form of pancreatitis.

Conclusion:
A higher level of IgG4 can accompany the finding of a pancreatic carcinoma; however, the IgG4 value is increased by no more than 20% above the so-called serum IgG4 limit value. Determination of IgG4 is not a suitable marker for differential diagnostics between the autoimmune form of pancreatitis and a pancreatic carcinoma, as was originally assumed, and it is possible to agree with opinions that an at least twofold increase in IgG4 of the blood serum is a significant diagnostic sign for the autoimmune form of pancreatitis and the entire group of diseases designated as IgG4-associated diseases.

Key words:
IgG4 – autoimmune pancreatitis – carcinoma of the pancreas

Zdroje

1. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastronterol 2006; 41(7): 613–625.

2. Kamisawa T, Nakajima H, Egawa N et al. IgG4-related sclerosing disease incorporated sclerosing pancreatitis,cholangitis, sialoadenitis and retroperitoneal fibrosis with lymphadenopathy. Pancreas 2006; 6(1–2): 132–137.

3. Okazaki K, Chiba T. Autoimmune-related pancreatitis. Gut 2002; 51(1): 1–4.

4. Kamisawa T, Tu Y, Nakajima H et al. Sclerosing cholecystitis associated with autoimmune pancreatitis. World J Gastroenterol 2006; 12(23): 3736–3739.

5. Mendes FD, Jorgensen R, Keach J et al. Elevated serum IgG4 concentration in patiens with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101(9): 2070–2075.

6. Hirano K, Kawabe T, Komatu Y et al. High-rate pulmonary involvement in autoimmune pancreatitis. Intern Med J 2006; 36(1): 58–61.

7. Kamisawa T, Chen PY, Tu Y et al. Autoimmune pancreatitis metachronously associated with retroperitoneal fibrosis with IgG4-positive plasma cell infiltration. World J Gastroetnerol 2006; 12(18): 2655–2657.

8. Kamisawa T. Clinical subtypes of autoimmune pancreatitis. Intern Med 2005; 44(8): 785–786.

9. Kloeppel G, Detlefsen S, Chari ST. Autoimmune pancreatitis: their clinicopathological characteristics of the subtype with granulocytic epithelial lesions. J Gastroenterol 2010; 45(8): 787–793.

10. Hari ST, Kloeppel G, Zhang I et al. The Autoimmune Pancreatitis International Cooperative Study group. Histologic and Clinical Subtypes of Autoimmune Pancreatitis: The Honolulu Consensus Document. Pancreas 2010; 39: 549–554.

11. Shimosegawa T, Chari ST, Frulloni L et al. International Concensus Diagnostic Criteria for Autoimmune Pancreatitis. Guidelines of the International Association of Pancreatology. Pancreas 2011; 40(3): 352–358.

12. Chari ST, Takahashi N, Levy MJ et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7(10): 1097–1103.

13. Hamano H, Kawa S, Horoucni A et al. High serum IgG4 concentration in patiens with sclerosing pancreatitis. N Engl J Med 2001; 344(10): 732–738.

14. Inoue HMD, Miyatani HMD, Sawada YMD. A case of pancreatic cancer with autoimune pancreatitis. Pancreas 2006; 33(2): 209–209.

15. Kamisawa T, Chen PY, Tu Y et al. Pancreatic cancer with a high serum IgG4 concentration. World J Gastroenterol 2006; 12(38): 6225–6228.

16. Sakashita F, Tanahashi T, Yamaguchi K. Case of pancreatic tail cancer associated with auto-immune pancreatitis. Japan J Gastroenterol 2006; 39: 78–83.

17. Raina A, Krasinskas AM, Greer JB et al. Serum immunoglobulin fraction4 in pancreatic cancer. Elevation not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132(1): 48–53.

18. Erkelens GW, Vleggaar FP, Lesterhuis W et al. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet 1999; 354(9172): 43–44.

19. Moon SH, Kim MH, Park DH et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer?A prospective outcome study. Gut 2008; 57(12): 1704–1712.

20. Tabata T, Kamisawa T, Takuma K et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic diseases. Intern Med 2011; 50(2): 69–75.

21. Ghazale A, Chari ST, Smyrk TE et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102(8): 1646–1653.

22. Morselli-Labate AM, Pezzilli R. Usefulness of serum IgG4 in the diagnosis and follow-up of autoimmune pancreatitis: a systemic literature review and meta analysis. J Gastroenterol Hepatol 2009; 24(1): 15–36.